
浏览全部资源
扫码关注微信
纸质出版日期:2012
移动端阅览
刘宾, 牛乐, 黄明宜. 抵当汤对大鼠慢性前列腺炎的治疗作用及机制[J]. 中国实验方剂学杂志, 2012,18(20):231-235.
LIU Bin, NIU Le, HUANG Ming-yi. Experimental Study on the Therapeutic Effect of Didang Decoction on Chronic Prostatitis[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(20): 231-235.
目的: 探讨抵当汤对慢性前列腺炎的治疗作用及其机制。 方法: 将50只大鼠随机分为假手术组(蒸馏水10 mL·kg-1)、病理模型组(蒸馏水10 mL·kg-1)、抵当汤高剂量组(16.2 g·kg-1)、抵当汤低剂量组(8.1 g·kg-1)、阳性对照组(前列康片 0.5 g·kg-1)。在大鼠前列腺双侧背叶分别注入消痔灵注射液0.1 mL
5周后形成慢性前列腺炎;假手术组于同样部位同样方法注入0.9%氯化钠注射液0.1 mL。各组大鼠于术后开始ig给药
假手术组及病理模型组ig蒸馏水
连续给药5周后
检测血浆血栓素B2(TXB2)、6-酮-前列腺素F1α(6-keto-PGF1α)及TXB2
6-keto-PGF1α及二者比值(T/K)
检测血清肿瘤坏死因子-α(TNF-α)。病理形态学观察前列腺组织腺体管腔、分泌物、间质炎细胞、纤维组织。 结果: 与模型组血浆TXB2(819±224)μg·L-1相比
抵当汤高、低剂量组及前列康组血浆TXB2(915±195)
(1 068±64)
(1 101±317)μg·L-1
均有不同程度的降低(P<0.05);与模型组6-keto-PGF1α(576±187)μg·L-1相比
抵当汤高、低剂量组及前列康组6-keto-PGF1α(1071±197)
(838±197)
(911±199)μg·L-1显著升高(P<0.05);与模型组T/K(2.89±1.04)相比
抵当汤高、低剂量组及前列康组T/K(0.88±0.23)
(1.34±0.31)(1.28±0.49)
比值显著降低(P<0.05);与模型组TNF-α(410±129)μg·L-1相比
抵当汤高、低剂量组及前列康组TNF-α为(144±35)
(312±69)
(238±84)μg·L-1
显著降低(P<0.05)。病理结果显示抵当汤高剂量组大鼠前列腺组织腺体管腔、腺体分泌物、间质炎细胞、纤维组织增生评分较低
差异均具有显著性。 结论: 抵当汤降低TXB2
升高6-keto-PGF1α水平
使T/K比值大幅降低
同时对慢性前列腺炎大鼠血液中的炎症介质TNF-α有抑制作用。
Objective:To explore effect and its mechanism of Didang decoction on chronic prostatitis. Method: Fifty rats were randomly divided into control group (distilled water 10 mL·kg-1)
model group (distilled water 10 mL·kg-1)
Didang decoction high-dose group (16.2 g·kg-1)
low-dose group (8.1 g·kg-1)
positive control group (Qianliekang 0.5 g·kg-1). Chronic prostatitis model was induced by Xiaozhiling injection 0.1 mL. The corresponding drugs were given. The plasma level of thromboxane B2 (TXB2)
6-keto prostaglandin F1α (6-keto-PGF1α)
the tumor necrosis factor-α(TNF-α) was measured. Prostate tissue was collected to observe prostate tissue gland secretion and lumen
interstitial inflammatory cells and fibrous tissue. Result: Compared with model group
plasma TXB level (819±224)μg·L-1
Didang decoction high-dose group
low-dose group and positive control group (915±195)
(1 068±64)
(1 101±317) μg·L-1
is significantly descreased (P<0.05). Compared with pathological model group 6-keto-PGF1α(576±187)μg·L-1
Didang decoction high-dose group
low-dose group and positive control group (1 071±197)
(838±197)
(911±199) μg·L-1 is significantly increased (P<0.05). Compared with pathological model group T/K(2.89±1.04)
Didang decoction high-dose group
low-dose group and positive control group(0.88±0.23)
(1.34±0.31)
(1.28±0.49) is significantly descreased (P<0.05). Compared with pathological model group TNF-α(410±129)μg·L-1
Didang decoction high-dose group
low-dose group and positive control group(144±35)
(312±69)
(238±84)μg·L-1 is significantly descreased (P<0.05). Pathological results show that Didang decoction high-dose group
prostate gland organization lumen
gland secretion
interstitial inflammatory cells
fibre hyperplasia with lower scores
with significant difference were. Conclusion: Didang decoction can lower TXB2
rise 6-keto-PGF1α level
make T/K ratio greatly reduced
at the same time for chronic prostatitis rats inflammation in the blood of the TNF-α possess the inhibition.
0
浏览量
5
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621